Evidence map›Paper›PMID 25917044›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2015

Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro.

Wenping Wang, Tingsong Xia, Xinpu Yu

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 110 citations in OpenAlex.

  1. Review
  2. World journal of gastroenterology · 2026
    Review
  3. Review
  4. Article
  5. Microbial threads in the tapestry of rheumatoid arthritis.The Journal of clinical investigation · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. FermentedNutrients · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Effect of Apremilast on LPS-induced immunomodulation and inflammation via activation of Nrf2/HO-1 pathways in rat lungs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  17. Therapeutic Potential of Bioactive Components fromInternational journal of molecular sciences · 2023
    Review
  18. Article
  19. Supplementation with postbiotic fromFrontiers in microbiology · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wenping WangDepartment of Gastroenterology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangsu, 214400, People's Republic of China.
Tingsong Xia
Xinpu Yu
Jiangyin People's Hospital · CNSoutheast University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS AND

objectiveWogonin has multiple pharmacological effects, including anti-inflammatory effects. Here, we hypothesize that wogonin can protect intestinal barrier function in lipopolysaccharide (LPS)-induced Caco-2 cells, which is an in vitro model of intestinal inflammation.

methodsWe measured intestinal barrier function in LPS-induced Caco-2 cells by using transepithelial electrical resistance (TEER) and transport of fluorescent markers. A quantitative (q) RT-PCR and immunofluorescent staining analysis was used to detect the expression of tight junction proteins (claudin-1 and ZO-1) in LPS-induced Caco-2 cells. We measured inflammatory molecules in LPS-induced Caco-2 cells using ELISA and qRT-PCR. In addition, the expression of TLR4, MyD88 and TAK1 and their interaction, and NF-κB activity in LPS-induced Caco-2 cells were investigated by western blot analysis and immune-precipitation.

resultsWe found that exposing Caco-2 cells to wogonin (10 and 50 μM for 24 h) attenuated the LPS-induced changes in TEER and transport of fluorescent markers. In addition, wogonin suppressed LPS-induced down-regulation of tight junction proteins (claudin-1 and ZO-1). Furthermore, LPS-induced up-regulation of inflammatory mediators, including interleukin (IL)-1β, IL-6 and IL-8, cyclooxygenase-2 (COX-2), inducible nitric oxide synthases (iNOS) were reduced after being pre-treated with wogonin. Moreover, wogonin not only inhibited the expression of TLR4, MyD88 and TAK1 and the interaction between these molecules, but also reduced NF-κB translocation to nucleus and its DNA-binding activity in LPS-induced Caco-2 cells.

conclusionOur results suggested that pre-treatment with wogonin could attenuate the TLR4-mediated inflammatory response and maintain intestinal barrier function in LPS-induced Caco-2 cells, thus might be a potential therapy for treating IBD.

Indexed as

Anti-Inflammatory AgentsAntioxidantsBiological Transport, ActiveCaco-2 CellsClaudin-1Electric ImpedanceFlavanonesHumansInflammation MediatorsInterleukinsIntestinesMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMyeloid Differentiation Factor 88NF-kappa BSignal TransductionAnti-Inflammatory AgentsAntioxidantsClaudin-1FlavanonesInflammation MediatorsInterleukinsMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMYD88 protein, humanMyeloid Differentiation Factor 88NF-kappa BTLR4 protein, humanToll-Like Receptor 4wogonin

Identifiers

PMID25917044
OpenAlexW2079479624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.